{
    "2020-07-20": [
        [
            {
                "time": "",
                "original_text": "上市8年翻29倍：如今赴港在即 泰格医药资质究竟如何？",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "上市",
                        "资质"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "明星基金经理调仓路线大曝光",
                "features": {
                    "keywords": [
                        "基金经理",
                        "调仓"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "最前线丨泰格医药通过港交所上市聆讯，或将实现“A+H”两地上市",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "聆讯",
                        "A+H",
                        "上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "国内第三家“A+H”CRO企业来了! 泰格医药通过港交所聆讯",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "A+H",
                        "CRO",
                        "聆讯"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "安信国际 | 新股前瞻：泰格医药 看点几何",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "新股",
                        "安信国际"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格医药通过港交所聆讯：募资最高15亿美元 即将招股",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "聆讯",
                        "募资",
                        "招股"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "方达控股(01521.HK)控股股东泰格医药拟于联交所主板上市",
                "features": {
                    "keywords": [
                        "方达控股",
                        "泰格医药",
                        "主板",
                        "上市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}